The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

The U.S. government advised American travelers age 60 and older not get a chikungunya vaccine as it investigates possible side effects. The Centers for Disease Control and Prevention and the Food and ...

An outbreak of a serious infection brought back to the UK by holidaymakers has led to two new vaccines being approved in the ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

Researchers say they've discovered an already approved migraine drug that can stop symptoms hours before a severe headache ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are recommending a pause in the use of the chikungunya vaccine, called Ixchiq, for adults age 60 and ...

New recommendations from the National Academies of Sciences, Engineering, and Medicine are asking scientists to dive into ...

Centres for Disease Control and Prevention (CDC) has issued an advisory urging American travellers over the age of 60 years ...